HAEM4:Follicular Dendritic Cell Sarcoma - Revision history

Bailey.Glen at 21:43, 4 December 2023

2023-12-04T21:43:35Z

← Older revision		Revision as of 16:43, 4 December 2023
Line 13:		Line 13:
	==Cancer Category/Type==		==Cancer Category/Type==

	[[Histiocytic and Dendritic Cell Neoplasms]] (WHO 4th ed.)<ref name=":0">Chan JKC, et al., (2017). Follicular dendritic cell sarcoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.</ref>		[[HAEM4:Histiocytic and Dendritic Cell Neoplasms]] (WHO 4th ed.)<ref name=":0">Chan JKC, et al., (2017). Follicular dendritic cell sarcoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.</ref>

	Stroma-derived neoplasms of lymphoid tissues (WHO 5th ed.)<ref name=":1">{{Cite journal\|last=Alaggio\|first=Rita\|last2=Amador\|first2=Catalina\|last3=Anagnostopoulos\|first3=Ioannis\|last4=Attygalle\|first4=Ayoma D.\|last5=Araujo\|first5=Iguaracyra Barreto de Oliveira\|last6=Berti\|first6=Emilio\|last7=Bhagat\|first7=Govind\|last8=Borges\|first8=Anita Maria\|last9=Boyer\|first9=Daniel\|date=2022-07\|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/35732829\|journal=Leukemia\|volume=36\|issue=7\|pages=1720–1748\|doi=10.1038/s41375-022-01620-2\|issn=1476-5551\|pmc=9214472\|pmid=35732829}}</ref>		Stroma-derived neoplasms of lymphoid tissues (WHO 5th ed.)<ref name=":1">{{Cite journal\|last=Alaggio\|first=Rita\|last2=Amador\|first2=Catalina\|last3=Anagnostopoulos\|first3=Ioannis\|last4=Attygalle\|first4=Ayoma D.\|last5=Araujo\|first5=Iguaracyra Barreto de Oliveira\|last6=Berti\|first6=Emilio\|last7=Bhagat\|first7=Govind\|last8=Borges\|first8=Anita Maria\|last9=Boyer\|first9=Daniel\|date=2022-07\|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/35732829\|journal=Leukemia\|volume=36\|issue=7\|pages=1720–1748\|doi=10.1038/s41375-022-01620-2\|issn=1476-5551\|pmc=9214472\|pmid=35732829}}</ref>
Line 247:		Line 247:
	==Links==		==Links==

	[[~~Inflammatory Pseudotumor~~-~~Like Follicular/Fibroblastic Dendritic Cell Sarcoma~~]]		[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma]]

	Put your links here (use "Link" icon at top of page)		Put your links here (use "Link" icon at top of page)

Bailey.Glen at 18:59, 3 November 2023

2023-11-03T18:59:06Z

@@ Line 1: / Line 1: @@
 {{Under Construction}}
 ==Primary Author(s)*==
@@ Line 257: / Line 262: @@
 <nowiki>*</nowiki>The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG TOC ==Cancer Category/Type== Histiocytic and Dendritic Cell Neopla..."

2023-11-03T18:26:39Z

Created page with "{{Under Construction}} ==Primary Author(s)*== Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG __TOC__ ==Cancer Category/Type== Histiocytic and Dendritic Cell Neopla..."

New page

{{Under Construction}}
==Primary Author(s)*==

Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG

__TOC__

==Cancer Category/Type==

[[Histiocytic and Dendritic Cell Neoplasms]] (WHO 4th ed.)<ref name=":0">Chan JKC, et al., (2017). Follicular dendritic cell sarcoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.</ref>

Stroma-derived neoplasms of lymphoid tissues (WHO 5th ed.)<ref name=":1">{{Cite journal|last=Alaggio|first=Rita|last2=Amador|first2=Catalina|last3=Anagnostopoulos|first3=Ioannis|last4=Attygalle|first4=Ayoma D.|last5=Araujo|first5=Iguaracyra Barreto de Oliveira|last6=Berti|first6=Emilio|last7=Bhagat|first7=Govind|last8=Borges|first8=Anita Maria|last9=Boyer|first9=Daniel|date=2022-07|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms|url=https://pubmed.ncbi.nlm.nih.gov/35732829|journal=Leukemia|volume=36|issue=7|pages=1720–1748|doi=10.1038/s41375-022-01620-2|issn=1476-5551|pmc=9214472|pmid=35732829}}</ref>

==Cancer Sub-Classification / Subtype==

Mesenchymal dendritic cell neoplasms (WHO 5th ed.)<ref name=":1" />

==Definition / Description of Disease==

Follicular dendritic cell sarcoma (FDCS) is a neoplasm with morphologic and immunophenotypic features of follicular dendritic cells, which are normally present in lymphoid follicles and are derived from mesenchymal cells of lymphoid tissues.

==Synonyms / Terminology==

Follicular dendritic cell tumor

Dendritic reticulum cell tumor (no longer used)

==Epidemiology / Prevalence==

Put your text here

==Clinical Features==

Put your text here

==Sites of Involvement==

*Extranodal sites (79%)
**Liver, spleen, and GI tract most common
**Any site may be involved
*Lymph nodes (~15%)<ref name=":2">{{Cite journal|last=Facchetti|first=Fabio|last2=Simbeni|first2=Matteo|last3=Lorenzi|first3=Luisa|date=2021-10|title=Follicular dendritic cell sarcoma|url=https://pubmed.ncbi.nlm.nih.gov/34837090|journal=Pathologica|volume=113|issue=5|pages=316–329|doi=10.32074/1591-951X-331|issn=1591-951X|pmc=8720404|pmid=34837090}}</ref>

==Morphologic Features==

Put your text here

==Immunophenotype<ref name=":0" /><ref name=":2" />==

{| class="wikitable sortable"
|-
!Finding!!Marker
|-
|Positive (lineage-defining)||One or more of CD21, CD23, CD35
|-
|Positive (frequent)||CXCL13, clusterin, podoplanin, fascin, vimentin
|-
|Positive (variable)
|CD68, EMA, S100
|-
|Negative (universal)||CD1a, langerin, CD34, CD45, lysozyme, CD163, MPO, CD3, CD79a, cytokeratins, HMB-45
|}

==Chromosomal Rearrangements (Gene Fusions)==

The following rearrangements have been reported in individual cases, but whether they are recurrent is not yet known.

{| class="wikitable sortable"
|-
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
|-
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5%
|-
|EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5%
|}

==Characteristic Chromosomal Aberrations / Patterns==

Although no recurrent chromosomal alterations have been identified in FDCS, the tumors often show complex karyotypes with loss of whole or partial chromosomes being the most frequent aberration. Losses frequently occur in regions harboring important tumor suppressor genes.<ref name=":2" />

==Genomic Gain/Loss/LOH==

Put your text here and/or fill in the table

{| class="wikitable sortable"
|-
!Chromosome Number!!Gain/Loss/Amp/LOH!!Region
|-
|EXAMPLE 8||EXAMPLE Gain||EXAMPLE chr8:0-1000000
|-
|EXAMPLE 7||EXAMPLE Loss||EXAMPLE chr7:0-1000000
|}

==Gene Mutations (SNV/INDEL)==

Put your text here and/or fill in the tables

{| class="wikitable sortable"
|-
!Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)
|-
|''CDKN2A''||Copy number loss||Tumor Suppressor|| ||
|-
|''NFKBIA''
|
|
|
|
|-
|''TP53''
|
|
|
|
|-
|''BIRC3''
|
|
|
|
|-
|''CCND2''
|
|
|
|
|-
|''BRAF''
|p.V600E
|
|
|0-19%
|-
|''TRAF3''
|
|
|
|
|-
|''TNFAIP3''
|
|
|
|
|-
|''RB1''
|
|
|
|
|-
|''CDK4/MDM2''
|
|
|
|
|-
|''PTEN''
|
|
|
|
|-
|''JAK2''
|
|
|
|
|-
|''SOCS3''
|
|
|
|
|-
|''BRCA1/BRCA2''
|
|
|
|
|-
|''KRAS''
|
|
|
|
|-
|''MYC''
|
|
|
|
|-
|
|
|
|
|
|-
|
|
|
|
|
|}

===Other Mutations===
{| class="wikitable sortable"
|-
!Type!!Gene/Region/Other
|-
|Concomitant Mutations||EXAMPLE IDH1 R123H
|-
|Secondary Mutations||EXAMPLE Trisomy 7
|-
|Mutually Exclusive||EXAMPLE EGFR Amplification
|}

==Epigenomics (Methylation)==

Put your text here

==Genes and Main Pathways Involved==

FDCS primarily shows alterations in the NF-κB signaling pathway. Unlike the dendritic cell and histiocytic neoplasms of hematopoietic origin, aberrations in the MAPK pathway are uncommon.

==Diagnostic Testing Methods==

The only current method of diagnosis is tissue biopsy with immunohistochemistry. FDCS must be differentiated from other mesenchymal dendritic cell neoplasms, histiocytic and dendritic cell neoplasms, and non-hematopoietic tumors such as carcinoma, sarcoma, or melanoma which may show histologic similarities.

==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)==

Put your text here

==Familial Forms==

*None known

==Other Information==

Put your text here

==Links==

[[Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma]]

Put your links here (use "Link" icon at top of page)

==References==
(use "Cite" icon at top of page)
<references />
===EXAMPLE Book===

#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

<nowiki>*</nowiki>The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.

HAEM4:Follicular Dendritic Cell Sarcoma - Revision history

Bailey.Glen at 21:43, 4 December 2023

Bailey.Glen at 18:59, 3 November 2023

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG __TOC__ ==Cancer Category/Type== Histiocytic and Dendritic Cell Neopla..."

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG TOC ==Cancer Category/Type== Histiocytic and Dendritic Cell Neopla..."